Hematologic Malignancies - Siteman Cancer Center

Hematologic MalignanciesLeukemia, Lymphoma, Myelomaand Stem Cell TransplantationClinical TrialsTo learn more about the clinical studies, or to enroll a patient,please contact the listed study coordinator at 314-454-8377.AML, newly diagnosedAcute Leukemia /MDSCALGB 10503 PI: Ravi Vij Study Coordinator:Ryan MonahanPhase II Study of Maintenance Therapy With DecitabineFollowing Standard Induction and Cytogenetic Risk-AdaptedIntensification in Previously Untreated Patients With AML< 60 Years.Notes: Newly dx de novo AML age 18-59, randomized to decitabinemaintenance after induction and risk adapted consolidation basedon cytogenetics to either HiDAC or auto transplant08-0126 PI: Ravi Vij Study Coordinator:Ryan MonahanSWOG S0521— A Randomized Trial of Maintenance VersusObservation for Patients with Previously Untreated Low andIntermediate Risk Acute Promyelocytic Leukemia (APL),Phase III.Notes: Low or intermediate risk APL 18 years and older withno prior systemic therapy or recurrent disease.06-0907 PI: Ravi Vij Study Coordinator:Alissa NelsonPhase II Trial of Lenalidomide in Older Patients (> 60 years)with Untreated Acute Myeloid Leukemia without Chromosome5q AbnormalitiesAML, relapsed refractory07-0227 PI: Geoffrey Uy Study Coordinator:Sandra LopezA Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide andCytarabine (AMD3100+MEC) in Relapsed or Refractory AML.Notes: Age 18-65 with either primary refractory AML, relapsed AMLwith initial CR less than 1 yr or in 2nd relapse or higher08-0017 PI: Keith Stockerl-GoldsteinStudy Coordinator:Alissa NelsonOpen Label Randomized Controlled Dose Escalating Phase IIStudy of AS1411 Combined with Cytarabine in the Treatmentof Patients with Primary Refractory or Relapsed Acute MyeloidLeukemia (AS1411-C-201).Notes: Refractory or relapsed AML and 18 years of age or older.MDS/AML, otherP2C 05-1159PI: Amanda CashenPhase II Study of the Histone Deacetylase Inhibitor PXD101for the Treatment of Myelodysplastic SyndromeNotes: 18 years old and up with a diagnosis of MDS, no morethan 2 previous lines of therapy and either ineligible or refusedallo transplant.08-0172 PI: Geoffrey Uy Study Coordinator:Alissa NelsonA Phase I/II Study of LBH589 plus Decitabine for PatientsAge > 60 Years with High Risk MDS or AMLNotes: Age > 60 with MDS (IPSS>2) or AML with no prior treatmentwith a hypomethylating agentCALGB 100103 PI: Ravi Vij Study Coordinator:Ryan MonahanA Phase II Study Of Allogeneic Transplant For Older PatientsWith AML In First Morphologic Complete Remission UsingA Non-Myeloablative Preparative Regimen.Notes: CR1, Fludarabine, Busulfan, Thymoglobulin conditioning07-0643 PI: John DiPersio Study Coordinator:Jeremy GabrielA Phase II Study of Active Immunotherapy With GRNVAC1,Autologous Mature Dendritic Cells Transfected With mRNAEncoding Human Telomerase Reverse Transcriptase, inPatients With Acute Myelogenous Leukemia in CompleteClinical Remission.Notes: Age 18-65 with AML in 1st or 2nd CR using dendriticcell vaccine directed against telomerase (hTERT)08-X139 PI:Camille Abboud Study Coordinator:Ryan MonahanPhase I Study of Oral Clofarabine Consolidation in Adults Aged60 and Older with Acute Myeloid LeukemiaStudy Coordinator:07-0916 PI: Ravi VijLiz ProcknowA Phase II study of intravenous Decitabine in combinationwith Arsenic Trioxide and Ascorbic Acid in patients withmyelodysplastic syndromesNotes: MDS defined by FAB classification.ALLCALGB 10403 PI: Ravi Vij Study Coordinator:Ryan MonahanAn Intergroup Phase II Clinical Trial for Adolescents and Youngadults with Untreated Acute Lymphoblastic Leukemia.Notes: Newly diagnosed and untreated ALL between the age of16 and 29.4